Loading...
XSHE
002688
Market cap558mUSD
Jul 10, Last price  
4.91CNY
1D
0.61%
1Q
-18.57%
Jan 2017
-51.39%
IPO
-11.21%
Name

Jinhe Biotechnology Co Ltd

Chart & Performance

D1W1MN
XSHE:002688 chart
P/E
137.11
P/S
1.31
EPS
0.04
Div Yield, %
2.04%
Shrs. gr., 5y
2.33%
Rev. gr., 5y
6.73%
Revenues
2.88b
+21.41%
444,386,448458,751,898590,218,256720,726,464770,405,138741,071,198839,805,8061,250,468,5331,495,686,2551,457,826,3591,628,890,0971,782,364,0811,814,638,9642,077,988,7302,077,988,7292,122,705,3172,122,705,3172,174,131,0332,370,626,9642,878,096,341
Net income
28m
-72.50%
15,869,57627,027,76352,753,94377,404,78889,576,88690,432,47877,209,561104,652,706164,129,159108,423,897163,628,887184,938,651117,324,53393,992,38093,992,388118,040,48675,616,37186,457,024100,200,69227,556,698
CFO
469m
-5.92%
11,637,20623,195,301118,049,223106,590,75488,806,099148,323,1430214,966,344292,411,55527,253,028117,174,643282,185,997258,079,960152,978,505124,471,194198,765,852498,423,937468,919,529
Dividend
Jun 06, 20250.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Founded in 1990 and headquartered in Dalian, China, Jinhe Biotechnology Co. Ltd. focuses on the development and distribution of animal health pharmaceuticals both domestically and internationally. The company provides chlortetracycline in a feed-grade formulation, an antimicrobial compound vital for preventing and treating conditions like white dysentery, enteritis, pneumonia, typhoid, paratyphoid, and cholera in poultry and livestock. Additionally, its offerings include chlortetracycline hydrochloride, utilized to combat pullorum disease, typhoid, swine enteritis, and other bacterial ailments such as paratyphoid and cholera. Jinhe Biotechnology extends its market reach globally, exporting these veterinary solutions to regions including the United States, Southeast Asia, Latin America, and Europe.
IPO date
Jul 13, 2012
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT